Salma Jabbour, MD, Rutgers Cancer Institute of New Jersey
Educational background
BA, University of Virginia
MD, University of Maryland School of Medicine
Internship, University of Maryland Medical Center
Residency in Radiation Oncology, Johns Hopkins School of Medicine
Research interests
I am interested in developing novel therapies for the treatment of lung cancers and gastrointestinal cancers in combination with radiation therapy. Many of these diseases still require significant improvements in outcomes, and breakthroughs such as immunotherapy may help patients live longer and control their cancers when combined with radiation therapy. Read More
March 25, 2019: In this month's Across the Consortium, the Big Ten CRC highlights research to detect cancer cells early in their development, and other advances from our member institutions. We also congratulate those who received hard-earned grants and leadership positions. Read More
March 8, 2019: A phase I Big Ten Cancer Research Consortium study for adult patients with relapsed or refractory Classical Hodgkin lymphoma is open for accrual at Masonic Cancer Center, University of Minnesota; the University of Illinois Cancer Center; the University of Wisconsin Carbone Cancer Center; and the University of Iowa Holden Comprehensive Cancer Center. The study, BTCRC-HEM15-027, will help determine the safety (maximum tolerated dose) and efficacy of ruxolitinib, which blocks the main pathway dysregulated in Hodgkin lymphoma, when combined with the immunotherapy drug nivolumab. Read More
March 1, 2019:Investigator Spotlight Shihuan Kuang, PhD, Purdue University Center for Cancer ResearchEducational background PhD in Physiology and Cell Biology: University of Alberta Research interests My lab mainly aims to understand the molecular regulation of stem cells in the adult skeletal muscle and adipose tissues, and how deregulation of certain signaling pathways underlie diseases including cancer. Read More
Feb. 19, 2019: In this month's Across the Consortium, the Big Ten CRC features the health initiatives our members are pursuing to reach communities at greatest risk of fatal cancer due to educational and health disparities; we celebrate some of the newest advances in cancer research at Big Ten universities; and we highlight our members' engagement with state and local leaders. Read More
Feb. 1, 2019:Thought Leader Perspectives: Acute Myeloid Leukemia Acute myeloid leukemia (AML), a rapidly progressive form of blood cancer that can occur at any age but mostly presents in patients age 60 and older, represents the most common cause of leukemia-related mortality in the United States and accounts for approximately 21,000 new cases and 10,000 deaths per year. For decades, the therapeutic progress in AML has been slower than in other cancers, which is in part due to the enormous genomic heterogeneity of the disease. Although the approval of several targeted agents by the FDA since April 2017 inaugurated an exciting new era in AML therapy, only a subset of patients are expected to benefit from these tailored treatment options. The great progress in understanding the... Read More
Jan. 20, 2019: In this month's Across the Consortium, we highlight a variety of research initiatives — from genetic testing for quicker diagnosis to new projects that help us better understand biology in order to prevent and kill cancer faster — and we remember those who recently passed away and had a profound influence in cancer research and advocacy. Read More
Jan. 10, 2019: The Big Ten Cancer Research Consortium (Big Ten CRC) recently named Thomas G. Sors, PhD, assistant director of the Purdue Institute of Inflammation, Immunology and Infectious Disease (PI4D), to the Big Ten CRC Steering Committee, representing the Purdue University Center for Cancer Research. The Big Ten CRC Steering Committee comprises one representative from each member institution and meets regularly to review activities and guide policies for the consortium. Read More
Subscribe to the Big Ten CRC Newsletter
X
Facebook
YouTube